Literature DB >> 2548863

Muscle bio-energetics in acute glycolytic block: in vivo phosphorus-nuclear magnetic resonance study of iodo-acetate injected rats.

Z Argov1, D Nagle, U Giger, J S Leigh.   

Abstract

In vivo phosphorus nuclear magnetic resonance spectroscopy of muscle was performed at rest, during work and during postexercise recovery in rats injected with iodo-acetate (IA) (35-40 mg.kg-1, intra-arterially), in order to follow bio-energetic changes in muscle with acute glycolytic block. Three animals with contracture had very low ratios of phosphocreatine:inorganic phosphate (PCr:Pi) at rest (0.5-0.9). The PCr:Pi were normal at rest (6.9 +/- 2.0, +/- 2 SD) in all other rats. Exercise-induced continuous accumulation of phosphomonoesters (PME), the characteristic finding of glycolytic block, was observed. The end-exercise levels of PME correlated with the degree of block measured in vitro. During steady-state work, induced by nerve stimulation at four frequencies, PCr:Pi values were significantly lower (p less than 0.02) than the control values at 0.25, 1.0 and 2.0 Hz. The ATP levels fell during exercise to reach 75% +/- 7% of initial values. The recovery of PCr:Pi from exercise and the disappearance of PME were slow. Two animals which survived the IA injection demonstrated much lower PME accumulation 18 h later. It is concluded that in acute muscle glycolytic block: (1) energy metabolism is impaired during exercise and also at rest, (2) accumulating PME can serve as an indicator of the degree of glycolytic block, (3) ATP levels fall during work, and (4) postexercise recovery is slow. The findings are compared with 31P-NMR observations in chronic muscle glycolytic disorders.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548863     DOI: 10.1007/BF02332211

Source DB:  PubMed          Journal:  Eur J Appl Physiol Occup Physiol        ISSN: 0301-5548


  17 in total

1.  Physiological characteristics of skeletal muscles of dogs and cats.

Authors:  L C Maxwell; J K Barclay; D E Mohrman; J A Faulkner
Journal:  Am J Physiol       Date:  1977-07

2.  Bioenergetics of intact human muscle. A 31P nuclear magnetic resonance study.

Authors:  D J Taylor; P J Bore; P Styles; D G Gadian; G K Radda
Journal:  Mol Biol Med       Date:  1983-07

3.  Applications of 31P NMR to clinical biochemistry.

Authors:  B Chance
Journal:  Ann N Y Acad Sci       Date:  1984       Impact factor: 5.691

4.  Cytosolic phosphorylation potential.

Authors:  R L Veech; J W Lawson; N W Cornell; H A Krebs
Journal:  J Biol Chem       Date:  1979-07-25       Impact factor: 5.157

5.  Phosphorus magnetic resonance spectroscopy of partially blocked muscle glycolysis. An in vivo study of phosphoglycerate mutase deficiency.

Authors:  Z Argov; W J Bank; B Boden; Y I Ro; B Chance
Journal:  Arch Neurol       Date:  1987-06

6.  Excess purine degradation in exercising muscles of patients with glycogen storage disease types V and VII.

Authors:  I Mineo; N Kono; T Shimizu; N Hara; Y Yamada; S Sumi; K Nonaka; S Tarui
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

7.  Iodoacetate inhibition of glyceraldehyde-3-phosphate dehydrogenase as a model of human myophosphorylase deficiency (McArdle's disease) and phosphofructokinase deficiency (Tarui's disease).

Authors:  R A Brumback
Journal:  J Neurol Sci       Date:  1980-12       Impact factor: 3.181

8.  Phosphorus NMR spectroscopy study of muscular enzyme deficiencies involving glycogenolysis and glycolysis.

Authors:  D Duboc; P Jehenson; S Tran Dinh; C Marsac; A Syrota; M Fardeau
Journal:  Neurology       Date:  1987-04       Impact factor: 9.910

9.  Muscle energy metabolism in human phosphofructokinase deficiency as recorded by 31P nuclear magnetic resonance spectroscopy.

Authors:  Z Argov; W J Bank; J Maris; J S Leigh; B Chance
Journal:  Ann Neurol       Date:  1987-07       Impact factor: 10.422

10.  31P-NMR studies on an animal model of human defective muscle glycolysis.

Authors:  T Kuwabara; T Yuasa; T Miyatake
Journal:  Muscle Nerve       Date:  1986-02       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.